	US 7,575,873 B2
	Reagents for diagnosing, imaging and treating atherosclerotic disease
Joseph L. Witztum, Sand Diego, Calif. (US); Sotirios Tsimikas, San Diego, Calif. (US); and Wulf Palinski, San Diego, Calif. (US)
Assigned to The Regents of the University of California, Oakland, Calif. (US)
Filed on Nov. 12, 2003, as Appl. No. 10/706,659.
Application 10/706659 is a division of application No. 09/699131, filed on Oct. 26, 2000, granted, now 6,716,410.
Claims priority of provisional application 60/161493, filed on Oct. 26, 1999.
Prior Publication US 2004/0120893 A1, Jun. 24, 2004
Int. Cl. G01N 33/563 (2006.01); G01N 33/53 (2006.01); A61K 39/395 (2006.01)

U.S. Cl. 435—7.1 [436/512; 436/547; 435/7.21; 435/70.21; 424/130.1; 530/300; 530/350; 530/387.1]

8 Claims

1. An isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody having the binding specificity of the IK17 antibody;

wherein the human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody comprises the variable light chain encoded by the nucleotide sequence of SEQ ID NO:1 and the variable heavy chain encoded by the nucleotide sequence of SEQ ID NO:2;

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) is specific for oxidation specific epitopes found on copper-induced oidized low density lipoprotein (Cu—OxLDL) or malondialdehyde low density lipoportine (MDA-LDL);

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) does not bind to native LDL;

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) inhibits uptake of CuOxLDL by macrophages; and

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) binds the epitope in vivo at a detectably higher rate than the rate of binding to normal vasculature.